Related references
Note: Only part of the references are listed.Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis
Efstathios Kastritis et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis
Arnt V. Kristen et al.
EUROPEAN JOURNAL OF HEART FAILURE (2009)
Current treatment of AL amyloidosis
Giovanni Palladini et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone
D. Lebovic et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis
Tilmann Bochtler et al.
HAEMATOLOGICA (2008)
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis
Arnaud Jaccard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2007)
Non-invasive predictors of survival in cardiac amyloidosis
Arnt V. Kristen et al.
EUROPEAN JOURNAL OF HEART FAILURE (2007)
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
Ashutosh D. Wechalekar et al.
BLOOD (2007)
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone -: a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)
W Pönisch et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2006)
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
MA Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation
G Palladini et al.
BLOOD (2004)
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study
M Skinner et al.
ANNALS OF INTERNAL MEDICINE (2004)
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
A Dispenzieri et al.
BLOOD (2004)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease -: A Global Utilization of Strategies to Open occluded arteries (GUSTO)-IV substudy
SK James et al.
CIRCULATION (2003)
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins
A Dispenzieri et al.
LANCET (2003)
Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis
G Palladini et al.
CIRCULATION (2003)
Share Paper
